Viking Therapeutics(VKTX)
icon
搜索文档
Viking Therapeutics(VKTX) - 2023 Q3 - Earnings Call Transcript
2023-10-26 08:17
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Conference Call October 25, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Joon Lee - Truist Securities Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Joseph Pantginis - HC Wainwright Andy Hsieh - William Blair Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcom ...
Viking Therapeutics(VKTX) - 2023 Q3 - Quarterly Report
2023-10-26 05:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...
Viking Therapeutics(VKTX) - 2023 Q2 - Earnings Call Transcript
2023-07-27 08:36
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Joon Lee - Truist Securities Andy Hsieh - William Blair Yale Jen - Laidlaw & Co Thomas Smith - Leerink Partners Justin Zelin - BTIG Dylan Dupuis - Roth MKM Operator Welcome to the Viking Therapeutics Second Quart ...
Viking Therapeutics(VKTX) - 2023 Q2 - Quarterly Report
2023-07-27 04:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...
Viking Therapeutics(VKTX) - 2023 Q1 - Earnings Call Transcript
2023-04-27 08:55
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - Viking’s President and CEO Gregory Zante - CFO Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Securities Annabel Samimy - Stifel Jay Olson - Oppenheimer Andy Hsieh - William Blair Yale Jen - Laidlaw & Co Justin Zelin - BTIG Nazibur Rahman - Maxim Group Operator Welcome to the Viking Therapeutics Fi ...
Viking Therapeutics(VKTX) - 2023 Q1 - Quarterly Report
2023-04-27 05:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...
Viking Therapeutics(VKTX) - 2022 Q4 - Annual Report
2023-02-10 06:48
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-1073877 ( State or other jurisdict ...
Viking Therapeutics(VKTX) - 2022 Q4 - Earnings Call Transcript
2023-02-09 10:47
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ET Company Participants Stephanie Diaz - Investor Relations Brian Lian - President and Chief Executive Officer Gregory Zante - Chief Financial Officer Conference Call Participants Joon So Lee - Truist Securities Steven Seedhouse - Raymond James & Associates Joseph Pantginis - H.C. Wainwright Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Scott Henry - ROTH MKM Partners Justin Zelin - BTIG Nazibur Rahman ...